Alerts will be sent to your verified email
Verify Email
VENMAX
|
Venmax Drugs&Pharma
|
Chemo Pharma Labs
|
Emmessar Biotech&Nut
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-44.32 % | -4.51 % | 13.7 % |
|
5yr average Equity Multiplier
|
-0.19 | 1.01 | 1.24 |
|
5yr Average Asset Turnover Ratio
|
0.32 | 0.0 | 0.36 |
|
5yr Avg Net Profit Margin
|
-30.94 % | 0.0 | 71.53 % |
|
Price to Book
|
4.33 | 1.45 | 2.46 |
|
P/E
|
0.0 | 0.0 | 46.31 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 0.0 | 68.18 Days |
|
Inventory Days
|
24.83 Days | 0.0 | 62.21 Days |
|
Days Receivable
|
0.0 | 0.0 | 10.88 Days |
|
Days Payable
|
189.56 Days | 0.0 | 199.95 Days |
|
5yr Average Interest Coverage Ratio
|
-318.36 | 794.39 | 815.2 |
|
5yr Avg ROCE
|
-45.33 % | -3.17 % | 19.97 % |
|
5yr Avg Operating Profit Margin
|
-50.41 % | 0.0 | -101.39 % |
|
5 yr average Debt to Equity
|
-0.64 | 0.01 | 0.0 |
|
5yr CAGR Net Profit
|
n/a | n/a | 0.0 |
|
5yr Average Return on Assets
|
187.49 % | -4.13 % | 10.86 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
23.13 % | 27.89 % | 59.53 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | 1.34 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Venmax Drugs&Pharma
|
Chemo Pharma Labs
|
Emmessar Biotech&Nut
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|